You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

New Drug Approved for Advanced Renal Cell Cancer

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000414312.49083.9b
Drug Watch
Abstract

* Axitinib (Inlyta), a tyrosine kinase inhibitor, has recently been approved for the treatment of advanced kidney cancer when other therapy hasn't been successful. Taken orally twice a day, axitinib prevents angiogenesis, tumor growth, and cancer progression.

* Common adverse effects include diarrhea, hypertension, fatigue, anorexia, nausea, loss of voice, hand–foot syndrome, weight loss, vomiting, weakness, and constipation.

Author Information

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: dianea@son.jhmi.edu.

© 2012 Lippincott Williams & Wilkins, Inc.